Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26979999 | 1.00 | ADORA2A (0.55) | ADORA2AADORA2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL7396869 | 0.86 | KDM4E (0.62) | ADORA2AADORA2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL7396871 | 0.86 | KDM4E (0.62) | ADORA2AADORA2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL6046607 | 0.86 | ADORA2A (0.55) | ADORA2AADORA2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL5759762 | 0.86 | ADORA2A (0.55) | ADORA2AADORA2BKDM4EMEN1ALDH1A1 | |
| SCHEMBL27130019 | 0.83 | GLA (0.58) | ADORA2AADORA2B | |
| SCHEMBL26980696 | 0.83 | GLA (0.58) | ADORA2AADORA2B | |
| SCHEMBL7731332 | 0.79 | ADORA2A (0.52) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7731341 | 0.79 | ADORA2A (0.52) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL26979963 | 0.79 | GLA (0.72) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2024-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | MRGPRX4, MRGPRX1, MRGPRX2 | ADORA2A 207/4885ADORA2B 262/4885KDM4E 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.